Cargando…

Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study

BACKGROUND: Proton pump inhibitors (PPIs) are acid suppressants that are frequently prescribed in many countries to reduce heartburn. A potassium-competitive acid blocker (P-CAB; tegoprazan) was launched relatively recently that also inhibits gastric acid secretion. This study aimed to compare the h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Min-Gul, Im, Yong-Jin, Lee, Jong-Hwan, Kim, Eun-Young, Yeom, Sang Woo, Kim, Jong Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876560/ https://www.ncbi.nlm.nih.gov/pubmed/36714137 http://dx.doi.org/10.3389/fmed.2022.1076356

Ejemplares similares

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
por: Son, Mijeong, et al.
Publicado: (2022)

Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
por: Cho, Yu Kyung, et al.
Publicado: (2020)

Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
por: Lee, Kwang Jae, et al.
Publicado: (2019)

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
por: Rawla, Prashanth, et al.
Publicado: (2018)

Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
por: Choi, Yoon Jin, et al.
Publicado: (2022)

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker
por: Mori, Hideki, et al.
Publicado: (2019)

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
por: Sue, Soichiro, et al.
Publicado: (2021)

Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
por: Luo, Hua-Jun, et al.
Publicado: (2014)

Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
por: Hwang, Jun Gi, et al.
Publicado: (2019)

Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2022)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Pathophysiology of Potassium-competitive Acid Blocker–refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
por: Masaoka, Tatsuhiro, et al.
Publicado: (2018)

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023)

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
por: Oh, Minkyung, et al.
Publicado: (2023)

JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
por: Ku, Jin Mo, et al.
Publicado: (2023)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022)

Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials
por: Zhang, Mengran, et al.
Publicado: (2022)

A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis
por: Simadibrata, Daniel Martin, et al.
Publicado: (2022)

Histamine2-Receptor Antagonists, Proton Pump Inhibitors, or Potassium-Competitive Acid Blockers Preventing Delayed Bleeding After Endoscopic Submucosal Dissection: A Meta-Analysis
por: Jiang, Xin, et al.
Publicado: (2019)

Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease
por: Kim, Seung Han, et al.
Publicado: (2021)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth
por: Kim, Ji Yeon, et al.
Publicado: (2021)

Anti-Inflammatory Effects of Tegoprazan in Lipopolysaccharide-Stimulated Bone-Marrow-Derived Macrophages
por: Han, Gong-Ho, et al.
Publicado: (2023)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia
por: Komori, Hiroyuki, et al.
Publicado: (2019)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
por: Jung, Yoon Suk, et al.
Publicado: (2023)

Gastric polyps' regression after potassium‐competitive acid blocker cessation
por: Iwamuro, Masaya, et al.
Publicado: (2022)

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022)

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
por: Han, Sungpil, et al.
Publicado: (2023)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Influenza viral infection is a risk factor for severe illness in COVID-19 patients: a nationwide population-based cohort study
por: Hwang, Jeong-Hwan, et al.
Publicado: (2023)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study
por: Jeon, Hye Kyung, et al.
Publicado: (2023)

Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report
por: Shao, Yuyang, et al.
Publicado: (2022)

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020)

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
por: Lee, Jung Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pt4pppit1gh879drgn1nf6o4h3